Explore the groundbreaking potential of ibogaine in addiction therapy with Deborah Mash, Dr. Alan Davis, and Dr. Stacey Armstrong from Ohio State University’s Center for Psychedelic Research and Education. Learn about their initiative, funded by the Hoover Foundation, to collect real-world evidence from ibogaine users through an anonymous patient survey. Discover how your participation could influence FDA considerations, shape future clinical trials, and potentially save lives. Join a pivotal conversation on psychedelic therapy, safety, and ibogaine’s profound impact on addiction recovery.

In this episode of Psychedelic Breakthrough Addiction Therapies, Professor Dalibor Sames delves into his journey as a chemist and neuroscientist, sharing insights into his passion for chemistry from a young age to his groundbreaking work bridging the gap between chemistry and neuroscience. As he discusses his fascination with psychoactive compounds, particularly ibogaine, Professor Sames unfolds the potential of synthetic modifications to optimize the therapeutic effects of ibogaine while mitigating cardiac risks. Through his innovative approach, he envisions a transformative impact on neural disorders and broader healing mechanisms.

The scientific and anecdotal evidence surrounding the psychedelic substance Ibogaine continues to captivate both the medical community and those seeking alternatives for overcoming addiction. In an insightful conversation between Dr. Deborah Mash and Tom Feegel, CEO of Beond—an Ibogaine clinic in Cancun—critical themes emerge that highlight the potential of Ibogaine as a breakthrough in addiction therapy and cognitive enhancement.One key focus in Dr. Mash's conversation with Fegel is the importance of administering Ibogaine in medically superior facilities. Ibogaine, though potent in curbing opioid addiction and stimulating cognitive enhancement, poses risks, especially concerning cardiac health. While Ibogaine's reputation blossomed within the context of addiction recovery, the conversation pivots to explore its potential in treating a spectrum of other conditions, from PTSD to neurocognitive disorders.

In the quest for pioneering treatments for mental health disorders, the synergy between psychedelic breakthroughs and virtual reality (VR) technology is surfacing as a promising avenue. As explored in a recent podcast with industry experts, this innovative approach has the potential to retrain the brain and offer transformative experiences for those suffering from depression, anxiety, and addiction. Today's show we delve into the insights shared by our guests Shel Mann, a VR technology veteran, and Marguerite Manteau-Rao, a clinical social worker and digital therapeutics innovator, spotlighting the human brain's capacity for change and recovery.

Dr. Mash discusses the potential of Ibogaine as an addiction treatment, highlighting its recent attention in the New York Times and personal experiences with its effectiveness. They delved into the unique mechanism of action of Ibogaine, demonstrating how it works on a larger scale than other psychedelic molecules and opens a window of neuroplasticity during treatment. However, the speakers also discussed the challenges and opportunities surrounding Ibogaine, including its illegal status, limited research, and lack of availability in the US, particularly for vulnerable populations like veterans.

The journey through addiction is fraught with challenges that can shatter families and extinguish lives. As the world grapples with the ramifications of substance abuse, alternative therapies like ibogaine offer a beacon of hope. On this inaugural episode of Psychodelic Breakthrough were joined by Alex and Angela Hargrove. They share their personal journey through addiction and recovery with the help of ibogaine.Ibogaine therapy represents a pivotal moment for many individuals struggling with addiction, as evidenced by Alex Hargrove's powerful testament. Describing his collision with substance abuse, Hargrove articulates a narrative familiar to many: the descent into dependency fuelled by legal prescriptions. His tipping point wasn't simply the ibogaine experience, but the profound after-effects the next morning.